Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Phase 2 Completed 102 enrolled Takeda Affymax · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy and safety of Peginesatide Injection for the maintenance of anemia in patients with chronic renal failure who are on hemodialysis or do not require dialysis and who were previously treated with Darbepoetin Alfa.

Timeline

Start: 2008-09
Primary completion: 2009-12
Completion: 2009-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	peginesatide	Peptide	0.04 mg/kg	Subcutaneous
Subject	peginesatide	Peptide	0.16 mg/kg	Subcutaneous

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Summary

Timeline

Drugs

Indications